Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT06144125
Recruiting Phase 4

Prothrombin Complex Concentrate vs Fresh Frozen Plasma in Goal-directed Bleeding Management in Cardiac Surgery

NCT06144125 · tracked via the Priya Life Science South Korea tracker
Sponsor
Konkuk University Medical Center
Phase
Phase 4
Started
2026-03-27
Last updated
2026-06-17

Condition(s) studied

Cardiac Valve Disease

Investigational drug(s) / intervention(s)

fresh frozen plasma →prothrombin complex concentrate →

fresh frozen plasma: transfusion of fresh frozen plasma

prothrombin complex concentrate: prothrombin complex concentrate administration

Study summary

The primary endpoint of this study is the completion time of hemostasis treatment when administered Fresh frozen plasma (FFP) and frozen powder coagulation factor concentrate (PCC) in goal-directed bleeding management for cardiac surgery.

Eligibility

Sex
ALL
Min age
20 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria: * patients undergoing cardiac surgery Exclusion Criteria: * thrombocytopenia * oral anti-coagulant * anti platelet agents

Primary outcome measure(s)

  • treatment time — 1 min
    duration from the time of diagnosing CT-EXTEM prolongation (ordering PCC or FFP) to the time achieving bleeding control (completing administration of PCC or FFP)

Trial sites (1)

FacilityCityRegionStatus
Konkuk University Medical Center Seoul Seoul Recruiting

More Konkuk University Medical Center trials in South Korea

Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy Recruiting
Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness Recruiting
Mild ANH on Pre-bypass Coagulation Function During Cardiac Surgery Starting soon
Comparison of the Diagnosis Time of VET and SCL in Patients With Intraoperative Coagulopathy Starting soon
Fibrinogen Concentrates Versus Cryoprecipitate in Liver Transplant Surgery Starting soon

Other trials for the same condition

CORCYM Mitral, Aortic aNd Tricuspid Post-maRket Study in a reAl-world Setting Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06144125 on ClinicalTrials.gov ↗ ← All trials in South Korea